TRAIN-R: a cysteine-rich member of the TNF-receptor family
View Patent ↗Novel receptor in the TNF family: TRAIN-receptor.
1. An isolated polypeptide which comprises an amino acid sequence selected from the group consisting of:
(a) SEQ ID NO: 3;
(b) SEQ ID NO: 9;
(c) amino acid residues 26 to 417 of SEQ ID NO:3;
(d) amino acid residues 1 to 173 of SEQ ID NO:3;
(e) amino acid residues 26 to 173 of SEQ ID NO:3;
(f) amino acid residues 1 to 190 of SEQ ID NO:3;
(g) amino acid residues 26 to 190 of SEQ ID NO:3;
(h) amino acid residues 174 to 190 of SEQ ID NO:3;
(i) amino acid residues 174 to 417 of SEQ ID NO:3; and
(j) amino acid residues 191 to 417 of SEQ ID NO:3.
2. The polypeptide of claim 1 , comprising amino acid residues 26 to 173 of SEQ ID NO:3.
3. The polypeptide of claim 1 , further comprising a heterologous polypeptide selected from the group consisting of: an immunoglobulin polypeptide, a serum albumin polypeptide, a lipoprotein, an apolipoprotein and a transferrin polypeptide.
4. The polypeptide of claim 3 , wherein said heterologous polypeptide is a human immunoglobulin Fc domain.
5. The polypeptide of claim 2 , further comprising a heterologous polypeptide selected from the group consisting of: an immunoglobulin polypeptide, a serum albumin polypeptide, a lipoprotein, an apolipoprotein and a transferrin polypeptide.
6. The polypeptide of claim 5 , wherein said heterologous polypeptide is a human immunoglobulin Fc domain.
7. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
8. A composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier.
9. A composition comprising the polypeptide of claim 3 and a pharmaceutically acceptable carrier.
10. A composition comprising the polypeptide of claim 5 and a pharmaceutically acceptable carrier.